AcclaimIP-ad

Match Document Document Title
US20060173201 Process for the produciton of tibolone  
Disclosed is a process for the synthesis of 17β-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-ene-20-yne-3-on e (ti-bolone, 11) and intermediates useful for the synthesis thereof: (11).
US20090036659 METHOD OF DEUTERATING BENZYL-POSITION IN -O-BENZYL GROUP  
To provide a method for efficiently and industrially deuterating the benzyl position of a —O-benzyl group formed by introducing a benzyl group, a benzyloxymethyl group and the like as a protecting...
US20070238701 2-Methylene-1alpha-Hydroxy-18,19,21-Trinorvitamin D3 Analogs and Uses Thereof  
Compounds of formula I are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds are used in preparing pharmaceutical compositions and are useful...
US20050222098 Regulation of meiosis  
Compounds of Formula I and methods of regulating the meiosis in a mammalian germ cell which method comprises administering an effective amount of the compound of Formula I to a germ cell in need...
US20100064452 BLUE ANTHRAQUINONE DYES, PRODUCTION AND USE THEREOF  
The present invention concerns dyes of the general formula I where X and Y represent hydrogen, bromine or chlorine, but not simultaneously hydrogen;R represents F, Cl, Br, COOR1 or CF3;R′...
US20120196227 CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION, PATTERNING PROCESS, AND ACID-DECOMPOSABLE KETO ESTER COMPOUND  
A chemically amplified positive resist composition comprises an acid-decomposable keto ester compound of steroid skeleton which is insoluble in alkaline developer, but turns soluble in alkaline...
US20140315833 Cocrystalline DHEA Formulations  
A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen...
US20110003022 Composition and Method  
A process of obtaining a saponin-rich component from a plant of the Araliaceae family, the process comprising the steps of: (a) treating a portion of the plant with an extraction solvent in which...
US20070270391 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses  
This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting...
US20090076290 SELECTIVE OXIDATION OF TRITERPENES EMPLOYING TEMPO  
The present invention provides a process of preparing betulin-28-aldehyde from betulin. The process includes contacting betulin with a compound of formula (I), e.g., TEMPO...
US20130123223 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES  
The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as...
US20130165658 PROCESS FOR THE PREPARATION OF IODIDES  
This invention is directed to a process for the preparation of high yield alkyl or aryl iodide from its corresponding carboxylic acid using N-iodo amides.
US20100160264 CRYSTALLINE SOLID FORMS  
The present invention relates to the new crystalline solid form VI and VIII of tigecycline and processes for the production of form VI and VIII. It further relates to a new method for preparing...
US20060224004 Process for preparing ursodeoxycholic acid di-sodium 3,7-disulfate  
Process for preparing ursodeoxycholic acid di-sodium 3,7-disulfate comprising: a) reacting ursodeoxycholic acid with sulfamic acid to give ursodeoxycholic acid di-ammonium 3,7-disulfate; b)...
US20130225844 Method for Monofluoromethylation of Organic Substrates to Prepare Biologically Active Organic Compounds  
Described is a process for the preparation of monofluoromethylated organic biologically active compounds using monofluoromethylated reagents. Fluticasone Propionate and Fluticasone Furoate can be...
US20100081724 PROCESS OF OBTAINMENT OF TRANS-RESVERATROL AND/OR EMODIN AND NUTRACEUTICCAL COMPOSITIONS CONTAINING THEM  
Processes for the separation and purification of polyphenol trans-resveratrol and/or anthraquinone emodin from Polygonum cuspidatum and/or Rumex acetosa, by means of solvent selective extraction....
US20090281071 THERAPEUTIC AGENT FOR HYPERTENSION  
The present invention provides a novel hypertension therapeutic agent. The hypertension therapeutic agent of the present invention contains, as an active ingredient, a compound represented by...
US20110250137 RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION  
The invention relates to the compounds suitable for radiolabeling with a chelator free radioisotope and radiolabeled compounds of the general Formula I. Said compounds are ornithine or lysine...
US20080214515 Process for Preparing 3a(Beta)-7a(Beta)-Dihydroxy-6a(Beta)-Alkyl-5Beta-Cholanic Acid  
Process for preparing 3α-7α(β)-di-hydroxy-6α(β)-alkyl-5β-cholanic acid (I) in which R is a linear or branched C1-C5 alkyl and the relative intermediates 3α-hydroxy-6β-alkyl-7-keto-5β-cholanic...
US20110237556 (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-HYDROXYVITAMIN D3  
Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are...
US20100210569 Mitochondria-targeting antioxidant therapeutics  
The instant invention constitutes an unique subject matter as a whole which has four individual aspects: (1) a class of chiral, non-racemic, synthetic carnitinoid analog carrier molecules which...
US20140249122 ANTI-DIABETIC AMINOSTEROID DERIVATIVES  
The present invention relates to novel aminosteroid derivatives substituted in position 3 andor 6, and to the use thereof in the context of the treatment of type 2 diabetes and of insulin resistance.
US20110319643 Synthesis of an Azido Energetic Alcohol  
A method of forming an azido energetic alcohol includes converting an energetic diol to a cyclic sulfite, oxidizing the cyclic sulfite to a cyclic sulfate, and opening the cyclic sulfate. The...
US20060178520 Process for preparing medrogestone  
A method for preparing medrogestone by heterogeneously palladium-catalyzed isomerization from 17α-methyl-6-methylenepregn-4-ene-3,20-dione.
US20150005519 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES  
The present invention relates to pharmaceutical compositions comprising 4-pregenen-11β-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid...
US20090124591 Synthesis and Use of Cationic Steroids for Anti-Inflammatory Drug Therapy  
The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and...
US20140121190 USE OF 3-ALPHA-ANDROSTANEDIOL, OPTIONALLY IN COMBINATION WITH A PDE5 INHIBITOR, IN THE TREATMENT OF SEXUAL DYSFUNCTION  
The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of 3-alpha-androstanediol, preferably in combination with a type 5...
US20080058540 Method For Producing Trimethylsilyl Azide  
The present invention relate to a method for producing a trimethylsilyl azide represented by the formula (3): (CH3)3 SiN3 (3) which comprises reacting a trimethylsilyl chloride represented by the...
US20110262368 C21 THIOETHERS AS GLUCOCORTICOID RECEPTOR AGONISTS  
The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds...
US20060178350 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes  
The present invention relates to 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, compositions which comprise said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, and methods for treating...
US20130123217 TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS  
The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack...
US20140322738 SUBSTRATES FOR COVALENT TETHERING OF PROTEINS TO FUNCTIONAL GROUPS OR SOLID SURFACES  
The present invention provides haloalkane substrates, and linkers for connecting such substrates to functional elements (e.g., tags, labels, surfaces, etc.). Substrates and linkers described...
US20090054312 SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases  
Methods are provided for screening for SMIPs (small molecule inhibitors of p27 depletion). The SMIPs thus identified are useful for treating cancers and other proliferative diseases.
US20050143366 Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders  
The present invention relates to compounds of the formula or pharmaceutically acceptable salts thereof useful for the prophylaxis and treatment of degenerative bone disorders and for the...
US20120116064 HYBRID LIPID COMPOUNDS BASED ON PENTAERYTHRITOL, INTERMEDIATES, PREPARATION METHODS AND USE THEREOF  
This invention relates to a novel class of hybrid lipid compound based on pentaerythritol, their intermediates, preparation methods and uses thereof. Different kinds of functional groups such as...
US20130324747 Process for Industrial Production of 2-Methyl-1,4-Naphthaquinone  
The present invention describes a process for producing 2-methyl-1,4-naphthoquinone by oxidizing 2-methylnaphthalene with fresh hydrogen peroxide in the presence of glacial acetic acid without any...
US20080200441 ESTROGEN RECEPTOR MODULATORS ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE  
Selective estrogen receptor modulators, as well their related pharmaceutical compositions and methods of use, are provided herein. These estrogen receptor modulators include compounds that...
US20120296104 CAU-1-N3 ORGANIC-INORGANIC HYBRID SOLID, EQUIPPED WITH AN AZIDE GROUP, AND PROCESS FOR ITS PREPARATION  
The invention describes a crystallized hybrid solid with an organic-inorganic matrix, of a three-dimensional structure, containing an inorganic network of aluminum-based metal centers that are...
US20070254857 2Alpha-Methyl-19-Nor-(20S)-1Alpha-Hydroxy-Bishomopregnacalciferol and Its Uses  
This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound...
US20060148759 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses  
This invention discloses 2α-methyl-19-nor-vitamin D analogs, and specifically 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced...
US20120316145 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-BENZYLIDENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES  
The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-benzylidene derivatives of the formula I, in which Y and X are each as defined in the claims and the description, to a...
US20120190660 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIENE-11-ETHYNYLPHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES  
The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-ethynylphenyl derivatives of the formula I, in which R1 and X are each as defined in the claims and the description,...
US20080234504 Processes for preparation of 9-haloacetamidominocyclines  
The present invention provides substantially pure intermediates, 9-haloacetomidominocyclines, and process of preparing them that are useful for the preparation of glycylcyclines, specifically...
US20080119443 Certain lithocholic acid analogues that inhibit sialyltransferase  
Certain chemical entities chosen from compounds of Formula I: and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof are described....
US20150175650 SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF  
The present invention relates to the synthesis of ent-progesterone and intermediates thereof.
US20140275572 SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF  
The present invention relates to the synthesis of ent-progesterone and intermediates thereof.
US20090156843 PROCESS FOR AROMATIZING 19-NORANDROST-4-EN-3-ONES TO ESTRA-1,3,5(10)-TRIENES  
The present invention relates to a process for aromatizing 19-norandrost-4-en-3-ones (formula (II)) to astra-1,3,5(10)-trienes (formula (I))
US20120208788 Tetracycline Compounds  
The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein....
US20120135968 Tetracycline Compounds  
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein....
US20080085875 CRYSTALLINE FORMS OF 11SS-(4-ACETYLPHENYL)-20,20,21,21,21-PENTAFLUORO-17-HYDROXY-19-NOR-17A-PREGNA-4,9-DIEN-3-ONE  
The present invention relates to crystalline forms of 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-1 9-nor-17α-pregna-4,9-dien-3-one. The invention relates in particular to two...